Pl find enclosed press release and analyst presentation on Q1FY27 earnings and business updates of the Company
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 14 Aug 2026, 01:57 PM IST · BSE ID: 267d9e8c-5521-4534-9dba-cf1bfa146eb1
View Original BSE Filing (PDF)
💡
In Simple Terms
Alkem Laboratories' Q1 FY27 sales increased significantly, but its net profit decreased compared to the same period last year.
🤖 AI Summary
- Alkem Laboratories reported Q1 FY27 total revenue from operations of ₹37,402 million, a 10.9% YoY increase.
- Net Profit (after Non-Controlling interest) for Q1 FY27 was ₹5,200 million, reflecting a 21.7% YoY de-growth.
- India sales contributed 67.1% to total sales, growing 10.3% YoY to ₹24,978 million.
- International sales increased by 16.0% YoY, with Non-US sales up 34.5% to ₹4,785 million.
- EBITDA for Q1 FY27 stood at ₹7,661 million, a 3.7% YoY growth, with a margin of 20.5%.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue from Operations Q1 FY27
₹37,402 million
10.9%
Net Profit (after Non-Controlling interest) Q1 FY27
₹5,200 million
-21.7%
EBITDA Q1 FY27
₹7,661 million
3.7%
EBITDA Margin Q1 FY27
20.5%
India sales Q1 FY27
₹24,978 million
10.3%
International sales Q1 FY27
₹12,223 million
16.0%
R&D expenses Q1 FY27
₹1,502 million
🏢 How This Affects the Company
The company's domestic business continued to outperform the Indian Pharmaceutical Market by 100 bps, showing growth in seven key focused therapies. Strong growth in non-US international markets contributed to overall international sales increase.
Total Revenue from Operations increased by 10.9% YoY to ₹37,402 million. However, Net Profit (after Non-Controlling interest) decreased by 21.7% YoY to ₹5,200 million, while R&D expenses increased to 4.0% of total revenue from operations.
The Daman (India) Formulations facility received an Official Action Indicated (OAI) regulatory status in August 2026, which may require operational adjustments. The company also received 5 ANDA approvals in Q1 FY27 for the US market.
The Official Action Indicated (OAI) status at the Daman (India) Formulations facility introduces a regulatory risk that could impact future operations or approvals. Increased R&D spend to 4.0% of revenue indicates investment in future growth but impacts current profitability.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results announcement.
👤
Who Is Affected
All shareholders are affected by the company's Q1 FY27 financial performance, including the 21.7% YoY decrease in Net Profit to ₹5,200 million.
🔍
Management Signal
Management acknowledged areas for improvement in execution, operational, and regulatory priorities, while also highlighting investments in R&D, MedTech, and Biotech for future growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor net profit trend and margin improvement.
Updates on Daman facility OAI status — look for resolution progress.
Details on R&D and MedTech investments — assess future growth drivers.
MEDIUM RISK
The 21.7% YoY net profit decline and Daman facility's Official Action Indicated (OAI) status present notable risks.
💡 Investor Takeaway
Alkem Laboratories reported Q1 FY27 Total Revenue from Operations of ₹37,402 million, up 10.9% YoY. Net Profit, however, saw a 21.7% YoY de-growth to ₹5,200 million. International sales grew 16.0%, but the Daman facility received an Official Action Indicated (OAI) status.
⚖️ Strengths & Concerns
✅ Positives
- Total Revenue from Operations grew 10.9% YoY to ₹37,402 million in Q1 FY27, driven by India and international segments.
- India business sales grew 10.3% YoY to ₹24,978 million, outperforming the Indian Pharmaceutical Market by 100 bps.
⚠️ Concerns
- Net Profit (after Non-Controlling interest) decreased by 21.7% YoY to ₹5,200 million in Q1 FY27.
- EBITDA margin decreased to 20.5% in Q1 FY27 from 21.9% in Q1 FY26, despite a 3.7% YoY EBITDA growth.
📅 Company Track Record
Alkem Laboratories' Q1 FY27 consolidated revenue grew 10.95% to ₹37,401.5 Million, following strong FY26 performance with record EBITDA of ₹30,052 million and 14.6% Q4 revenue growth.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Alkem Laboratories' total revenue from operations in Q1 FY27?
Alkem Laboratories' total revenue from operations in Q1 FY27 was ₹37,402 million, representing a 10.9% increase compared to Q1 FY26.
What was Alkem Laboratories' Net Profit (after Non-Controlling interest) in Q1 FY27?
Alkem Laboratories reported a Net Profit (after Non-Controlling interest) of ₹5,200 million in Q1 FY27, which is a 21.7% de-growth YoY.
How did Alkem Laboratories' India business perform in Q1 FY27?
Alkem Laboratories' India sales grew by 10.3% YoY to ₹24,978 million in Q1 FY27, contributing 67.1% to total sales and outperforming the Indian Pharmaceutical Market by 100 bps.
What was the regulatory status of Alkem Laboratories' Daman (India) Formulations facility in August 2026?
Alkem Laboratories' Daman (India) Formulations facility received an Official Action Indicated (OAI) regulatory status in August 2026, following an inspection in April 2026.
What were Alkem Laboratories' R&D expenses in Q1 FY27?
Alkem Laboratories' R&D expenses for Q1 FY27 were ₹1,502 million, representing 4.0% of total revenue from operations.
Questions based on this BSE filing only. For information purposes.